Scynexis News

SCYNEXIS Q1 2024 GAAP EPS $0.01 Beats $(0.20) Estimate, Sales $1.400M Beat $303.000K Estimate

SCYNEXIS (NASDAQ:SCYX) reported quarterly earnings of $0.01 per share which beat the analyst consensus estimate of $(0.20) by 105 percent. The company reported quarterly sales of $1.400 million which

Benzinga18:37 ET

Express News | Scynexis : Ended Q1 2024 With Cash, Cash Equivalents & Investments of $94.2 Mln & Projects Cash Runway of More Than Two Years

Reuters17:31 ET

Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M

04:51 PM EDT, 05/08/2024 (MT Newswires) -- Earnings Flash (SCYX) SCYNEXIS Reports Q1 Revenue $1.4M

MT Newswires16:51 ET

Scynexis Projects a Cash Runway of More Than Two Years >SCYX

Scynexis Projects a Cash Runway of More Than Two Years >SCYX

Dow Jones16:45 ET

Express News | Scynexis Q1 Operating Expenses USD 10.881 Million

Reuters16:30 ET

Express News | Scynexis Reports First Quarter 2024 Financial Results and Provides Corporate Update

Reuters16:30 ET

Express News | Scynexis Q1 Net Income USD 411 Thousand

Reuters16:30 ET

Express News | Scynexis Q1 Product Revenue USD 1.373 Million

Reuters16:30 ET

Express News | Scynexis Q1 EPS USD 0.01

Reuters16:30 ET

Express News | Scynexis Q1 Basic EPS USD 0.01

Reuters16:30 ET

Express News | Scynexis Q1 Pretax Profit USD 942 Thousand

Reuters16:30 ET

Scynexis 1Q Rev $1.37M >SCYX

Scynexis 1Q Rev $1.37M >SCYX

Dow Jones16:30 ET

Press Release: SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate Update -- SCY-247's IND-enabling activities continue to progress, with initiation of Phase I anticipated in the s

Dow Jones16:30 ET

Scynexis 1Q Net $411,000 >SCYX

Scynexis 1Q Net $411,000 >SCYX

Dow Jones16:30 ET

Scynexis 1Q EPS 1c >SCYX

Scynexis 1Q EPS 1c >SCYX

Dow Jones16:30 ET

Scynexis | 10-Q: Quarterly report

Futu News16:06 ET · Announcements

Investors in SCYNEXIS (NASDAQ:SCYX) Have Unfortunately Lost 87% Over the Last Five Years

Yahoo FinanceMay 8 11:48 ET

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)

In vivo data demonstrated efficacy of SCY-247 in mouse model of invasive candidiasis caused by Candida glabrataSCY-247 showed in vitro activity against a broad range of pathogenic fungi, including azole-resistant strains

GlobeNewswireApr 30 16:05 ET

Buy Rating Affirmed for SCYNEXIS on Strong Financials and Promising Pipeline Prospects

TipRanksApr 11 11:15 ET

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ:SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections,

GlobeNewswireApr 9 16:05 ET